+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Analysis of the differences of serum protein mass spectrometry in patients with triple negative breast cancer and non-triple negative breast cancer

Analysis of the differences of serum protein mass spectrometry in patients with triple negative breast cancer and non-triple negative breast cancer

Tumour Biology 35(10): 9751-9757

The objective of the present study was to investigate differences of serum protein mass spectrometry in patients with triple negative breast cancer (TNBC) and non-TNBC and thus to search for candidate serum protein biomarkers for identification and diagnosis of TNBC. Thirty serum samples from patients with TNBC without any treatment and 30 serum samples from patients with non-TNBC without any treatment were detected by using two-dimensional gel electrophoresis and matrix-assisted laser dissociation tandem time-of-flight mass spectrometry (MALDI-TOF-MS). PDQest 7.0 software of Bio-Rad was adopted to screen differentially expressed proteins. Protein ID retrieval was conducted by using Mascot software to confirm the results of differential proteins. Two-dimensional gel electrophoresis profiles were obtained successfully. A total of 16 differential protein loci were discovered by analyzing patient sera of the two groups using two-dimensional gel electrophoresis analysis software. Ten differential proteins were identified by mass spectrometric analysis in the 16 differential proteins. Combined with database and literature search results, it is speculated that the specifically upregulated proteins and downregulated proteins including transthyretin, haptoglobin, and antitrypsin may be the potential markers for early diagnosis of TNBC. Comparing the TNBC patients with the non-TNBC patients, there are differences in serum protein compositions. The ten differential proteins discovered in the present study provide reference basis for further improving early diagnosis and identification and diagnosis index of TNBC. Especially, transthyretin, haptoglobin, and antitrypsin show dramatic significances for the early diagnosis of TNBC.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 051530136

Download citation: RISBibTeXText

PMID: 24972967

DOI: 10.1007/s13277-014-2221-5

Related references

Triple Negative Breast Cancer versus Non-Triple Negative Breast Cancer Treated with Breast Conservation Surgery Followed by Radiotherapy: A Systematic Review and Meta-Analysis. Breast Care 10(6): 413-416, 2016

The Triple-Negative Breast Cancer Database: an omics platform for reference, integration and analysis of triple-negative breast cancer data. Breast Cancer Research 16(6): 490, 2015

Cisplatin-gemcitabine therapy in metastatic breast cancer: Improved outcome in triple negative breast cancer patients compared to non-triple negative patients. Breast 19(3): 246-248, 2010

Differences in Multi-Modal Ultrasound Imaging between Triple Negative and Non-Triple Negative Breast Cancer. Ultrasound in Medicine and Biology 42(4): 882-890, 2016

Bevacizumab Addition in Neoadjuvant Treatment Increases the Pathological Complete Response Rates in Patients with HER-2 Negative Breast Cancer Especially Triple Negative Breast Cancer: A Meta-Analysis. Plos One 11(8): E0160148, 2017

Diagnostic and prognostic significance of serum apolipoprotein C-I in triple-negative breast cancer based on mass spectrometry. Cancer Biology and Therapy 17(6): 635-647, 2017

Hydrophobic Fractionation Enhances Novel Protein Detection by Mass Spectrometry in Triple Negative Breast Cancer. Journal of Proteomics and Bioinformatics 3(2): 1-10, 2010

Study on mouse model of triple-negative breast cancer: association between higher parity and triple-negative breast cancer. Targeted Oncology 10(1): 85-97, 2015

Molecular characteristics and metastasis predictor genes of triple-negative breast cancer: a clinical study of triple-negative breast carcinomas. Plos One 7(9): E45831, 2013

Differential cytotoxic and radiosensitizing effects of silver nanoparticles on triple-negative breast cancer and non-triple-negative breast cells. International Journal of Nanomedicine 10: 3937-3953, 2016

Prognostic value of androgen receptor expression in triple negative breast carcinomas: personal experience and comments on a review about Triple-negative breast cancer: treatment challenges and solutions by Collignon et al. Breast Cancer: Targets and Therapy Volume 8: 157-159, 2016

Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Disease 32(1-2): 35-48, 2012

Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer. Medical Oncology 28 Suppl 1: S75-S79, 2012

Triple- negative breast cancer ( triple - negative breast cancer ) - homogeneous or heterogeneous group of cancers ?. Polish Journal of Pathology 65(4 Suppl 2): S53-S61, 2015

Hydrophobic Proteome Analysis of Triple Negative and Hormone-Receptor-Positive-Her2-Negative Breast Cancer by Mass Spectrometer. Clinical Proteomics 6(3): 93-103, 2010